Skip to Content
Merck
CN

32097

Supelco

Etoricoxib

VETRANAL®, analytical standard

Synonym(s):

5-Chloro-3-[4-(methylsulfonyl)phenyl]-2-(2-methyl-5-pyridinyl)pyridine, 5-Chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H15ClN2O2S
CAS Number:
202409-33-4
Molecular Weight:
358.84
Beilstein:
8073797
MDL number:
MFCD06797512
UNSPSC Code:
41116107
PubChem Substance ID:
329753738
NACRES:
NA.24

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

analytical standard

Quality Level

100

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

storage temp.

2-8°C

SMILES string

CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1

InChI

1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

InChI key

MNJVRJDLRVPLFE-UHFFFAOYSA-N

Gene Information

human ... PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Etoricoxib is a non-steroidal cyclooxygenase-2 (COX-2) selective anti-inflammatory drug mostly used to treat patients suffering from osteoarthritis and rheumatoid arthritis.

Application

Etoricoxib may have been used as reference standard in liquid chromatography-tandem mass spectrometry method with atmospheric pressure chemical ionization (LC-APCI/MS/MS) method for determination of etoricoxib from human plasma.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H302,H310

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 4 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM4253
BCCM3026
BCCK9569
BCCF5705
BCCB6900

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tilman T Zittel et al.
Diseases of the colon and rectum, 56(6), 761-767 (2013-05-09)
Cyclo-oxygenase 2 inhibitors can be used for pain treatment after colorectal surgery. The aim of this study was to investigate whether the use of etoricoxib has negative effects on the perioperative outcome in colorectal surgery. Complication data from an advanced
Katherine F Croom et al.
Drugs, 69(11), 1513-1532 (2009-07-29)
Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Etoricoxib provided similar symptomatic relief to nonselective NSAIDs in patients with these conditions, and to celecoxib
Shruti Setia et al.
Pharmacological reports : PR, 64(3), 615-624 (2012-07-21)
Non-steroidal anti-inflammatory drugs (NSAIDs) act by inhibition of cyclooxygenase-2 (COX-2), which is overexpressed in cancer. The role of COX-2 and apoptosis were evaluated in 9,10-dimethylbenz(a)anthracene (DMBA)-induced lung cancer in rat and chemoprevention with indomethacin, a traditional NSAID and etoricoxib, a
E Chilet-Rosell et al.
Journal of public health (Oxford, England), 31(3), 434-445 (2009-03-17)
The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential
Yuhong Yuan et al.
Current pharmaceutical design, 13(22), 2237-2247 (2007-08-21)
Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the incidence of gastrointestinal (GI) adverse events (AEs) which occur with non-selective NSAIDs (ns-NSAIDs). Etoricoxib and lumiracoxib are regarded as second generation coxibs because of their higher COX-2 selectivity. There are
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service